First draft sequence of human proteome released
Researchers have mapped 90 percent of the human proteome, which could inform the development of new medicines.
List view / Grid view
Researchers have mapped 90 percent of the human proteome, which could inform the development of new medicines.
A simple co-culture assay that can assess anti-tumour T-cell cytotoxicity via luminescence and flow cytometry has been created.
Scientists suggest targeting the SARS-CoV-2 papain-like protease (PLpro) with inhibitors could prevent the spread of infection.
Topical delivery of a small interfering RNA (siRNA) using an ionic liquid complex significantly reduced levels of inflammatory cytokines and symptoms of psoriasis.
Researchers have implicated long non-coding RNAs in tumour progression and suggest they may be potential drug targets for cancers with p53 mutations.
Researchers suggest that targeting host proteins with drugs, rather than directly targeting enzymes or proteins on SARS-CoV-2 and related coronaviruses, could improve outcomes.
Scientist identified the mechanism through which temporal lobe epileptic seizures are sparked and that D-serine can interfere with this process, preventing seizures.
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
A team has identified 219 molecules and genes that influence the severity of COVID-19 in patients, providing information that could aid the development of therapeutics.
Researchers have shown that an siRNA nanomedicine can target BACE1 in a mouse model of Alzheimer's, restoring cognitive capacity.
Altering the mastoparan-L (mast-L) peptide found in Vespula lewisii wasp venom, researchers created several novel antimicrobial molecules.
The team demonstrated that expression of Bach2 protein and reduced mTORC1 activity is necessary for germinal B cells to become memory B cells.
A common SARS-CoV-2 mutation known as D614G should not impact on the efficacy of COVID-19 vaccines, a study has shown.
Emmanuelle Charpentier and Jennifer Doudna have been given the 2020 Nobel Prize in Chemistry for their discovery and development of CRISPR-Cas9 genome editing.
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.